Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1985 Feb;82(4):1232-6.
doi: 10.1073/pnas.82.4.1232.

Circulating hydroxy fatty acids in familial Mediterranean fever

Comparative Study

Circulating hydroxy fatty acids in familial Mediterranean fever

P S Aisen et al. Proc Natl Acad Sci U S A. 1985 Feb.

Abstract

Episodes of fever, serositis, and arthritis in familial Mediterranean fever (FMF) suggested circulating mediators of acute inflammation (e.g., neutrophil activation). The mean serum neutrophil-aggregating activity of 51 FMF patients was 2.5 +/- 0.2 cm2/min, compared to 1.0 +/- 0.1 cm2/min in 20 normal controls (P less than 0.0002). Lipid extracts of FMF sera retained neutrophil-aggregating activity and had UV absorbance peaks at 269 and 279 nm, indicating the presence of lipids with a conjugated triene structure. Chromatography of extracts yielded peaks that were coeluted with reference dihydroxyicosatetraenoic acids, had UV absorbance peaks at 259, 269, and 279 nm, and possessed neutrophil-aggregating activity. The presence of leukotriene B4 was excluded by chromatography following methyl-esterification. Monohydroxy compounds identified in FMF extracts by gas chromatography/mass spectrometry included 5-hydroxyicosatetraenoic acid, and 9- and 13-hydroxyoctadecadienoic acids. Hydroxy acids were present in 19 of 31 FMF sera and absent in extracts of sera from 8 patients with active systemic lupus erythematosus, 7 with fever from infection, and 12 normal controls. The finding of circulating mono- and dihydroxy fatty acids in FMF suggests that defects in the formation or elimination of these compounds might play a role in the pathogenesis of FMF.

PubMed Disclaimer

References

    1. Am J Med. 1967 Aug;43(2):227-53 - PubMed
    1. N Engl J Med. 1951 May 24;244(21):786-90 - PubMed
    1. J Immunol. 1973 Jul;111(1):33-7 - PubMed
    1. J Cell Biol. 1974 Sep;62(3):594-609 - PubMed
    1. N Engl J Med. 1974 Oct 31;291(18):932-4 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources